TABLE 1.
Treatment (first generation) | IC50 (μM) of the following strain at the indicated time:
|
|||
---|---|---|---|---|
3D7
|
W2
|
|||
48 h (second-generation rings) | 96 h (third-generation rings) | 48 h (second-generation rings) | 96 h (third-generation rings) | |
Azithromycin | 8.67 ± 0.02 | 0.0527 ± 0.0091 | 1.46 ± 0.21 | 0.0310 ± 0.0085 |
Ciprofloxacin | 9.44 ± 0.06 | 3.04 ± 0.51 | 24.9 ± 8.6 | 1.75 ± 0.010 |
Clindamycin | >100 | 0.00881 ± 0.0051 | >100 | 0.00312 ± 0.00011 |
Doxycycline | 5.32 ± 0.53 | 0.453 ± 0.12 | 3.30 ± 0.95 | 0.211 ± 0.020 |
Rifampin | 2.99 ± 1.1 | 2.83 ± 0.67 | 0.274 ± 0.066 | 0.528 ± 0.19 |
Chloroquine | 0.00564 ± 0.0022 | 0.00849 ± 0.0030 | 0.0452 ± 0.0084 | 0.130 ± 0.036 |
Parasites were treated for 48 h, starting at the ring stage (first generation). Parasitemia of new rings (second generation) was determined by flow cytometry after 48 h or after an additional 48 h of growth in drug-free medium (third generation). Data are the averages ± standard deviations of two independent experiments, each performed in duplicate.